3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Lung Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Ovarian Neoplasms
2
Melanoma
2
Esophageal Neoplasms
2
Carcinoma, Renal Cell
2
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Diseases
1
Gestational Trophoblastic Disease
1
Gastro-enteropancreatic neuroendocrine tumor
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Merkel Cell
1
Carcinoid Tumor
1
Breast Neoplasms
1
Advanced Non-Small Cell Lung Cancer
1
Interventions
Docetaxel
6
Gemcitabine
3
Carboplatin
3
lorlatinib
2
cemiplimab
2
Vinorelbine
2
S 1 (combination)
2
Pemetrexed
2
Erlotinib Hydrochloride
2
Cisplatin
2
Cetuximab
2
zimberelimab
1
surufatinib
1
sintilimab
1
quemliclustat
1
pemigatinib
1
pembrolizumab
1
nimotuzumab
1
fludarabine
1
WW Domain-Containing Oxidoreductase
1
Paclitaxel
1
Interleukin-2
1
Gene Expression Profiling
1
Drug Therapy
1
Cyclophosphamide
1
Capecitabine
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Non-Small Cell Lung Cancer
×
zimberelimab
×
Thoracic
×
Clear all
NCT05676931
2026-06-01
EDGE-Lung
Gilead Sciences
Phase 2
Active not recruiting
400 enrolled